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S.T. Donell2, I.M. Clark1. 1University of East Anglia, Norwich, UNITED
KINGDOM, 2Norfolk & Norwich University Hospital, Norwich, UNITED
KINGDOM
Purpose: Cartilage destruction in osteoarthritis (OA) is thought to be
mediated by extracellular proteases. The main focus of research to date
has been on the role of two enzyme families; the matrix metalloproteases
(MMPs) with respect to cartilage collagen breakdown, and enzymes
from the ‘a disintegrin and metalloprotease domain with thrombospondin
motifs’ (ADAMTS) family with respect to cartilage aggrecan loss. It is
now known that there are around 561 proteases in the human genome
(the ‘degradome’): 21 aspartyl, 148 cysteine, 186 metallo-, 178 serine
and 28 threonine proteases. The expression of the vast majority of these
genes in cartilage is unknown. We have therefore proﬁled the complete
degradome in cartilage from patients with either OA or fracture to the
neck of femur (NOF), giving a more complete picture of proteolysis in
this tissue and disease.
Methods: Cartilage was collected at total hip replacement surgery and
snap frozen in liquid nitrogen. Cartilage was ground under liquid nitrogen
in a freezer mill and RNA puriﬁed by a combination of TRIzol (Invitrogen)
and RNeasy (Qiagen). RNA was reverse transcribed and gene expression
assessed by quantitative real-time PCR using Taqman low density arrays
on the ABI Prism 7900.
Results: Expression of 560 proteases and inhibitor genes was detectable
in cartilage using this methodology. Preliminary analysis shows that
approximately 197 proteases are differentially expressed in OA cartilage
compared to NOF at a statistical signiﬁcance of p< 0.05 (79 metallo-,
50 serine-, 41 cysteine-, 6 aspartyl-, 2 threonine proteases and 19
protease inhibitors). At a signiﬁcance of p< 0.0001, there were 3 aspartyl,
14 cysteine, 15 metallo-, 12 serine proteases and 5 inhibitors which are
differentially regulated in OA.
Conclusions: This is the most comprehensive analysis of protease gene
expression in cartilage to date. It has identiﬁed several protease genes
not previously reported to be expressed or regulated in cartilage and
provides the foundation on which to build functional studies.
A23 EXPRESSION OF HTRA1 IN HUMAN OA CHONDROCYTES
LEADS TO MATRIX DEGRADATION, INHIBITION OF MATRIX
SYNTHESIS, AND THE EXPRESSION OF A HYPERTROPHIC
PHENOTYPE
P.G. Mitchell, M.A. Carozza, J. Brittain, D.D. McKinley, K.L. Dufﬁn,
E. Zhen, S. Chandrasekhar, Y-W. Qian, A. Boodhoo. Eli Lilly,
Indianapolis, IN, USA
Purpose: Expression of the serine proteinase HtrA1 is upregulated in hu-
man osteoarthritic (OA) cartilage. To understand the link between HtrA1
expression and pathology, the enzyme was both overexpressed in normal
bovine chondrocytes, and knocked-down in human OA chondrocytes. The
effects of overexpression and knockdown of HtrA1 on 35S incorporation
into the extracellular matrix, and on the expression of genes related to
hypertrophy, were monitored. Finally, peptides resulting from treatment
of human aggrecan with recombinant HtrA1 were determined via mass
spectrometry.
Methods: Bovine chondrocytes and human OA chondrocytes (joint re-
placement surgery), were isolated by sequential digestion with protease
type XIV (Sigma) and collagenase type II (Worthington). Overexpression
of HtrA1 was obtained via electroporation using Amaxa technology. Gene
expression was determined via Taqman analysis using speciﬁc primer
probe sets for each gene. Aggrecan synthesis was determined by plating
chondrocytes on Cytostar T plates in the presence of 5mCi 35S, and
then measuring incorporation of label into the matrix on a Wallac Trilux
scintillation counter. siRNA transfections of human chondrocytes were
carried out using Dharmafect 4 lipid at 0.4 ml/well of 96 well plates.
SmartPool HtrA1 siRNA and non-targeting control siRNA (NT3) were from
Ambion. Enzyme digests of human aggrecan were carried out with HtrA1
(1:20 ratio) in Tris/NaCl/CaCl2, pH 7.5 buffer over a 7 day period with
fresh enzyme added on Day 3.
An LTQ ion trap mass spectrometer with a Surveyor HPLC system
(ThermoFinnigan) was used for peptide identiﬁcation. MS/MS spectra
were searched against protein databases using both Sequest and X!
Tandem database searching algorithms
Results: Taqman analysis of RNA derived from one healthy and 7 human
OA cartilage samples demonstrated a similar disease-associated upreg-
ulation of HtrA1 mRNA as had been previously reported. Treatment of
bovine chondrocytes with recombinant HtrA1 led to decreased 35S sulfate
incorporation into the extracellular matrix. No recovery of 35S sulfate
incorporation was observed up to 5 days post-removal of HtrA1. Overex-
pression of HtrA1 in bovine chondrocytes led to an expression-related
decrease in matrix 35S sulfate incorporation. HtrA1 overexpression in
bovine chondrocytes also led to hypertrophic gene expression changes,
including increases in expression of ADAMTS-5 and cathepsin K, and
a decrease in expression of type II collagen. HtrA1 siRNA treatment of
human OA chondrocytes led to >95% reduction in HtrA1 mRNA. This
was accompanied by signiﬁcant increases in both basal and BMP-7
induced incorporation of 35S sulfate into the cell matrix. MS/MS analysis
of recombinant HtrA1 digests of human aggrecan identiﬁed 28 distinct
peptides.
Conclusions: These studies demonstrate that expression of HtrA1 in
chondrocytes has functional consequences with respect to the ability of
chondrocytes to form and maintain an appropriate extracellular matrix,
and a correctly differentiated phenotype. HtrA1 can potentially act either
directly or indirectly to: (1) degrade extracellular matrix proteins such as
aggrecan, (2) inhibit matrix synthesis, and (3) upregulate expression of a
hypertrophic phenotype. These data suggest that inhibition of HtrA1 activ-
ity in cartilage is a useful therapeutic objective for treating osteoarthritis.
A24 INHIBITION OF MATRIX METALLOPROTEINASES
ENHANCES IN VITRO REPAIR OF THE MENISCUS
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Purpose: Damage or injury of the meniscus is associated with the onset
and progression of knee osteoarthritis. Previous studies have shown that
the intrinsic repair capacity of the meniscus is inhibited by inﬂammatory
cytokines, such as interleukin 1 (Il-1). The goal of this study was to in-
vestigate the role of matrix metalloproteinases (MMPs) on the integration
of juxtaposed meniscal tissue in an inﬂammatory microenviroment. Using
an in vitro meniscal repair model system, we examined the hypothesis
that inhibition of MMPs in the presence of Il-1 will enhance the repair of
meniscal lesions.
Methods: Explants (8mm diameter, 3mm thick) were harvested from the
outer one-third of porcine medial menisci. To simulate a full-thickness tear,
a 4mm diameter central core was punched out and reinserted. Explants
were cultured for 14 days at 37ºC, 5% CO2 in the presence of 100 pg/mL
recombinant porcine Il-1 alpha and the following MMP inhibitors (EMD
Biosciences): GM 6001, which is a broad spectrum MMP inhibitor, MMP-2
inhibitor I, MMP-2/MMP-9 inhibitor I, MMP-3 inhibitor II, MMP-8 inhibitor I,
and MMP-13 inhibitor. At the end of the culture period, the interfacial
shear strength of the repair was determined using a push-out test. Total
speciﬁc MMP activity in the media was also assessed using a quenched
ﬂuorescent peptide.
Figure 1. GM 6001 inhibits IL-1 mediated MMP activity. Total speciﬁc MMP
activity in the culture media over time was measured using a quenched
ﬂuorescent substrate (n = 10−12 samples per treatment group). The bars
indicate the mean ﬂuorescence units normalized by the wet weight of
the meniscal tissue ± standard error. a: p< 0.05 compared to all other
treatments. b: p< 0.005 compared to GM 6001. c: p< 0.005 compared to
IL-1 + GM 6001 and GM 6001.
